Eosinophilic esophagitis: Emerging therapies and future perspectives

Gastroenterology Clinics of North America

Volumn 43, Issue 2, 2014, Pages 385-394

  Straumann, Alex ^a  

^a Swiss EoE Research Network   (Switzerland)

Author keywords

CRTH2 antagonists; Disease monitoring; Eosinophilic esophagitis; Esophageal distensibility; Esophageal string test; IL 13 antagonist; IL 4 antagonist

Indexed keywords

CHEMOKINE RECEPTOR ANTAGONIST; CHEMOKINE RECEPTOR CCR3 ANTAGONIST; CORTICOSTEROID; INTERLEUKIN 13; INTERLEUKIN 13 MONOCLONAL ANTIBODY; INTERLEUKIN 4; MEPOLIZUMAB; MONOCLONAL ANTIBODY; OC 000459; PLACEBO; RESLIZUMAB; UNCLASSIFIED DRUG;

ALLERGY TEST; DIET RESTRICTION; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; EOSINOPHILIC ESOPHAGITIS; ESOPHAGUS DILATATION; ESOPHAGUS FUNCTION; FOOD ALLERGY; HUMAN; LONG TERM CARE; OUTCOME ASSESSMENT; PATIENT MONITORING; PERSONALIZED MEDICINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; REVIEW; RISK BENEFIT ANALYSIS; TREATMENT DURATION; FORECASTING;

EOSINOPHILIC ESOPHAGITIS; FORECASTING; HUMANS;

EID: 84899969419     PISSN: 08898553     EISSN: 15581942     Source Type: Journal    
DOI: 10.1016/j.gtc.2014.02.005     Document Type: Review

References (39)

1. Attwood S.E., Smyrk T.C., Demeester T.R., et al. Esophageal eosinophilia with dysphagia. A distinct clinicopathologic syndrome. Dig Dis Sci 1993, 38:109-116.
2. Straumann A., Spichtin H.P., Bernoulli R., et al. Idiopathic eosinophilic esophagitis: a frequently overlooked disease with typical clinical aspects and discrete endoscopic findings. Schweiz Med Wochenschr 1994, 124:1419-1429. [in German with English abstract].
3. Furuta G.T., Liacouras C., Collins M.H., et al. Eosinophilic esophagitis in children and adults: a systematic review and consensus recommendations for diagnosis and treatment. Gastroenterology 2007, 133:1342-1363.
4. Liacouras C.A., Furuta G.T., Hirano I., et al. Eosinophilic esophagitis: updated consensus recommendations for children and adults. J Allergy Clin Immunol 2011, 128:3-20.
5. Straumann A., Aceves S.S., Blanchard C., et al. Pediatric and adult eosinophilic esophagitis: similarities and differences. Allergy 2012, 67:477-490.
6. Liacouras C.A., Wenner W.J., Brown K., et al. Primary eosinophilic esophagitis in children: successful treatment with oral corticosteroids. J Pediatr Gastroenterol Nutr 1998, 26:380-385.
7. Konikoff M.R., Noel R.J., Blanchard C., et al. A randomized, double-blind, placebo-controlled trial of fluticasone propionate for pediatric eosinophilic esophagitis. Gastroenterology 2006, 131:1381-1391.
8. Schaefer E.T., Fitzgerald J.F., Molleston J.P., et al. Comparison of oral prednisone and topical fluticasone in the treatment of eosinophilic esophagitis: a randomized trial in children. Clin Gastroenterol Hepatol 2008, 6:165-173.
9. Dohil R., Newbury R., Fox L., et al. Oral viscous budesonide is effective in children with eosinophilic esophagitis in a randomized, placebo-controlled trial. Gastroenterology 2010, 139:418-429.
10. Straumann A., Conus S., Degen L., et al. Budesonide is effective in adolescent and adult patients with active eosinophilic esophagitis. Gastroenterology 2010, 139:1526-1537.
11. Alexander J.A., Jung K.W., Arora A.S., et al. Swallowed fluticasone improves histologic but not symptomatic response of adults with eosinophilic esophagitis. Clin Gastroenterol Hepatol 2012, 10:742-749.
12. Straumann A., Conus S., Degen L., et al. Long-term budesonide maintenance treatment is partially effective for patients with eosinophilic esophagitis. Clin Gastroenterol Hepatol 2011, 9:400-409.
13. Straumann A., Conus S., Grzonka P., et al. Anti-interleukin-5 antibody treatment (mepolizumab) in active eosinophilic esophagitis: a randomised, placebo-controlled, double-blind trial. GUT 2010, 59:21-30.
14. Assa'ad A.H., Gupta S.K., Collins M.H., et al. An antibody against IL-5 reduces numbers of esophageal intraepithelial eosinophils in children with eosinophilic esophagitis. Gastroenterology 2011, 141:1593-1604.
15. Spergel J.M., Rothenberg M.E., Collins M.H., et al. Reslizumab in children and adolescents with eosinophilic esophagitis: results of a double-blind, randomized, placebo-controlled trial. J Allergy Clin Immunol 2012, 129:456-463.
16. Straumann A., Hoesli S., Bussmann Ch, et al. Anti-eosinophil activity and clinical efficacy of the CRTH2 antagonist OC000459 in eosinophilic esophagitis. Allergy 2013, 68:375-385.
17. Kelly K.J., Lazenby A.J., Rowe P.C., et al. Eosinophilic esophagitis attributed to gastroesophageal reflux: improvement with an amino acid-based formula. Gastroenterology 1995, 109:1503-1512.
18. Henderson C.J., Abonia J.P., King E.C., et al. Comparative dietary therapy effectiveness in remission of pediatric eosinophilic esophagitis. J Allergy Clin Immunol 2012, 129:1570-1578.
19. Gonsalves N., Yang G.Y., Doerfler B., et al. Elimination diet effectively treats eosinophilic esophagitis in adults; food reintroduction identifies causative factors. Gastroenterology 2012, 142:1451-1459.
20. Lucendo A.J., Arias Á., González-Cervera J., et al. Empiric 6-food elimination diet induced and maintained prolonged remission in patients with adult eosinophilic esophagitis: a prospective study on the food cause of the disease. J Allergy Clin Immunol 2013, 131:797-804.
21. Schoepfer A.M., Gonsalves N., Bussmann C., et al. Esophageal dilation in eosinophilic esophagitis: effectiveness, safety and impact on the underlying inflammation. Am J Gastroenterol 2010, 105:1062-1070.
22. Anti-inflammatory drug discovery in 2012, 1-4. RSC Drug Discovery, London, Series, No 26. J.I. Levin, S. Laufer (Eds.).
23. H)2-type allergic inflammatory response. J Allergy Clin Immunol 2001, 108:954-961.
24. Rothenberg M.E., Mishra A., Brandt E.B., et al. Gastrointestinal eosinophils in health and disease. Adv Immunol 2001, 78:291-328.
25. Yamaguchi Y., Suda T., Suda J., et al. Purified interleukin 5 supports the terminal differentiation and proliferation of murine eosinophilic precursors. J Exp Med 1988, 167:43-56.
26. Mishra A., Hogan S.P., Lee J.J., et al. Fundamental signals that regulate eosinophil homing to the gastrointestinal tract. J Clin Invest 1999, 103:1719-1727.
27. Garcia-Zepeda E.A., Rothenberg M.E., Ownbey R.T., et al. Human eotaxin is a specific chemoattractant for eosinophil cells and provides a new mechanism to explain tissue eosinophilia. Nat Med 1996, 2:449-456.
28. Forssmann U., Uguccioni M., Loetscher P., et al. Eotaxin-2, a novel CC chemokine that is selective for the chemokine receptor CCR3, and acts like eotaxin on human eosinophil and basophil leukocytes. J Exp Med 1997, 185:2171-2176.
29. Blanchard C., Wang N., Stringer K.F., et al. Eotaxin-3 and a unique conserved gene-expression profile in eosinophilic esophagitis. J Clin Invest 2006, 116:536-547.
30. Pettipher R., Hansel T.T., Armer R. Antagonism of the prostaglandin D2 receptors DP1 and CRTH2 as an approach to treat allergic diseases. Nat Rev Drug Discov 2007, 6:313-325.
31. Pettipher R., Vinall S.L., Xue L., et al. Pharmacologic profile of OC000459, a potent, selective, and orally active D prostanoid receptor 2 antagonist that inhibits mast cell-dependent activation of T helper 2 lymphocytes and eosinophils. J Pharmacol Exp Ther 2012, 340:473-482.
32. Gonsalves N., Doerfler B., Hirano I. Long term maintenance therapy with dietary restriction in adults with eosinophilic esophagitis. Gastroenterology 2011, 140. [abstract], S-180-S-181.
33. Kagalwalla A.F., Amsden K., Shah A., et al. Cow's milk elimination: a novel dietary approach to treat eosinophilic esophagitis. J Pediatr Gastroenterol Nutr 2012, 55:711-716.
34. Wills-Karp M., Finkelman F.D. Untangling the complex web of IL-4- and IL-13-mediated signaling pathways. Sci Signal 2008, 1(51):pe55.
35. Wenzel S., Ford L., Pearlman D., et al. Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med 2013, 368:2455-2466.
36. Nicodème F., Hirano I., Chen J., et al. Esophageal distensibility as a measure of disease severity in patients with eosinophilic esophagitis. Clin Gastroenterol Hepatol 2013, 11:1101-1107.
37. Furuta G.T., Kagalwalla A.F., Lee J.J., et al. The oesophageal string test: a novel, minimally invasive method measures mucosal inflammation in eosinophilic oesophagitis. Gut 2013, 62:1395-1405.
38. Kwiatek M.A., Hirano I., Kahrilas P.J., et al. Mechanical properties of the esophagus in eosinophilic esophagitis. Gastroenterology 2011, 140:82-90.
39. Schoepfer A.M., Safroneeva E., Bussmann C., et al. Delay in diagnosis of eosinophilic esophagitis increases risk for stricture formation in a time-dependent manner. Gastroenterology 2013, 145:1230-1236.